

A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACM

NCT06976606

Status RECRUITING
Sponsor Lexeo Therapeutics
Enrollment 40 participants

Key Eligibility Criteria

Inclusion (5)

- Adults with a clinical diagnosis of ACM as defined by the 2010 revised Task Force Criteria (TFC)
- Documentation of a pathogenic or likely pathogenic truncating variant in PKP2
- Frequent premature ventricular contractions (PVCs)
- Patients must have an ICD placed prior to enrollment
- Left ventricular ejection fraction (LVEF) \geq 50% for Part A participants. Left ventricular ejection fraction (LVEF) \geq 40% for Part B participants.

Exclusion (4)

- Evidence of variant(s) in addition to PKP2 that meet standard criteria to be considered pathogenic or likely pathogenic for an arrhythmogenic cardiomyopathy.
- A history of other cardiac abnormalities as specified in the protocol.
- New York Heart Association symptoms of heart failure of Class IV at the time of consent.
- A history of prior gene transfer therapy.

Locations (6 total)

Leland Stanford Junior University, Redwood City, California, United States
Johns Hopkins University, Baltimore, Maryland, United States
Northshore University Healthsystem Research Institute, Columbia, Maryland, United States
... and 3 more locations